Global Antisense Oligonucleotide Therapy for the Nervous System Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
The global Antisense Oligonucleotide Therapy for the Nervous System market size is projected to grow from US$ 3938 million in 2024 to US$ 10620 million in 2030; it is expected to grow at a CAGR of 18.0% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Antisense Oligonucleotide Therapy for the Nervous System Industry Forecast” looks at past sales and reviews total world Antisense Oligonucleotide Therapy for the Nervous System sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Therapy for the Nervous System sales for 2023 through 2029. With Antisense Oligonucleotide Therapy for the Nervous System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotide Therapy for the Nervous System industry.
This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Therapy for the Nervous System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotide Therapy for the Nervous System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense Oligonucleotide Therapy for the Nervous System market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Therapy for the Nervous System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Therapy for the Nervous System.
United States market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Antisense Oligonucleotide Therapy for the Nervous System players cover Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Therapy for the Nervous System market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antisense Oligonucleotides (ASOs) are a class of nucleic acid drugs designed to target specific RNA molecules within cells. They work by binding to complementary RNA sequences, which can modulate gene expression in various ways. ASOs have been developed to treat a wide range of genetic and other diseases
The global Antisense Oligonucleotide Therapy for the Nervous System market size is projected to grow from US$ 3938 million in 2024 to US$ 10620 million in 2030; it is expected to grow at a CAGR of 18.0% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Antisense Oligonucleotide Therapy for the Nervous System Industry Forecast” looks at past sales and reviews total world Antisense Oligonucleotide Therapy for the Nervous System sales in 2022, providing a comprehensive analysis by region and market sector of projected Antisense Oligonucleotide Therapy for the Nervous System sales for 2023 through 2029. With Antisense Oligonucleotide Therapy for the Nervous System sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotide Therapy for the Nervous System industry.
This Insight Report provides a comprehensive analysis of the global Antisense Oligonucleotide Therapy for the Nervous System landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antisense Oligonucleotide Therapy for the Nervous System portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antisense Oligonucleotide Therapy for the Nervous System market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antisense Oligonucleotide Therapy for the Nervous System and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antisense Oligonucleotide Therapy for the Nervous System.
United States market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Antisense Oligonucleotide Therapy for the Nervous System is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Antisense Oligonucleotide Therapy for the Nervous System players cover Ionis Pharmaceuticals, Biogen, Sobi, Nippon Shinyaku, Jazz Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Therapy for the Nervous System market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Intrathecal Injection
- Intravenous Injections
- Other
- Neuromuscular Diseases
- hATTR
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Intrathecal Injection
- Intravenous Injections
- Other
- Neuromuscular Diseases
- hATTR
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Ionis Pharmaceuticals
- Biogen
- Sobi
- Nippon Shinyaku
- Jazz Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2030
2.1.2 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Antisense Oligonucleotide Therapy for the Nervous System by Country/Region, 2019, 2023 & 2030
2.2 Antisense Oligonucleotide Therapy for the Nervous System Segment by Type
2.2.1 Intrathecal Injection
2.2.2 Intravenous Injections
2.2.3 Other
2.3 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type
2.3.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
2.4 Antisense Oligonucleotide Therapy for the Nervous System Segment by Application
2.4.1 Neuromuscular Diseases
2.4.2 hATTR
2.4.3 Other
2.5 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application
2.5.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
3 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET SIZE BY PLAYER
3.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Player
3.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2019-2024)
3.1.2 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2019-2024)
3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM BY REGION
4.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024)
4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Annual Revenue by Country/Region (2019-2024)
4.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.4 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.5 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.6 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
5.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
5.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024)
6.2 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
6.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
7.2 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
7.3 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System by Region (2019-2024)
8.2 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
8.3 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET FORECAST
10.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.1.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2025-2030)
10.2.1 United States Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.2 Canada Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.3 Mexico Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.4 Brazil Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.3.1 China Antisense Oligonucleotide Therapy for the Nervous System Market Forecast
10.3.2 Japan Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.3 Korea Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.4 Southeast Asia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.5 India Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.6 Australia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2025-2030)
10.4.1 Germany Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.2 France Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.3 UK Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.4 Italy Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.5 Russia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.5.1 Egypt Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.2 South Africa Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.3 Israel Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.4 Turkey Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.6 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Type (2025-2030)
10.7 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
11 KEY PLAYERS ANALYSIS
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Information
11.1.2 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Ionis Pharmaceuticals Main Business Overview
11.1.5 Ionis Pharmaceuticals Latest Developments
11.2 Biogen
11.2.1 Biogen Company Information
11.2.2 Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.2.3 Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Biogen Main Business Overview
11.2.5 Biogen Latest Developments
11.3 Sobi
11.3.1 Sobi Company Information
11.3.2 Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.3.3 Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sobi Main Business Overview
11.3.5 Sobi Latest Developments
11.4 Nippon Shinyaku
11.4.1 Nippon Shinyaku Company Information
11.4.2 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.4.3 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Nippon Shinyaku Main Business Overview
11.4.5 Nippon Shinyaku Latest Developments
11.5 Jazz Pharmaceuticals
11.5.1 Jazz Pharmaceuticals Company Information
11.5.2 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.5.3 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Jazz Pharmaceuticals Main Business Overview
11.5.5 Jazz Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2030
2.1.2 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Antisense Oligonucleotide Therapy for the Nervous System by Country/Region, 2019, 2023 & 2030
2.2 Antisense Oligonucleotide Therapy for the Nervous System Segment by Type
2.2.1 Intrathecal Injection
2.2.2 Intravenous Injections
2.2.3 Other
2.3 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type
2.3.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
2.4 Antisense Oligonucleotide Therapy for the Nervous System Segment by Application
2.4.1 Neuromuscular Diseases
2.4.2 hATTR
2.4.3 Other
2.5 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application
2.5.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
3 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET SIZE BY PLAYER
3.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Player
3.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2019-2024)
3.1.2 Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2019-2024)
3.2 Global Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM BY REGION
4.1 Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024)
4.2 Global Antisense Oligonucleotide Therapy for the Nervous System Annual Revenue by Country/Region (2019-2024)
4.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.4 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.5 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
4.6 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
5.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
5.3 Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024)
6.2 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
6.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024)
7.2 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
7.3 Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System by Region (2019-2024)
8.2 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024)
8.3 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY FOR THE NERVOUS SYSTEM MARKET FORECAST
10.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.1.1 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.1.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.1.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2 Americas Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2025-2030)
10.2.1 United States Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.2 Canada Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.3 Mexico Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.2.4 Brazil Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3 APAC Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.3.1 China Antisense Oligonucleotide Therapy for the Nervous System Market Forecast
10.3.2 Japan Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.3 Korea Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.4 Southeast Asia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.5 India Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.3.6 Australia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4 Europe Antisense Oligonucleotide Therapy for the Nervous System Forecast by Country (2025-2030)
10.4.1 Germany Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.2 France Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.3 UK Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.4 Italy Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.4.5 Russia Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5 Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Forecast by Region (2025-2030)
10.5.1 Egypt Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.2 South Africa Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.3 Israel Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.5.4 Turkey Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
10.6 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Type (2025-2030)
10.7 Global Antisense Oligonucleotide Therapy for the Nervous System Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Antisense Oligonucleotide Therapy for the Nervous System Forecast
11 KEY PLAYERS ANALYSIS
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Information
11.1.2 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Ionis Pharmaceuticals Main Business Overview
11.1.5 Ionis Pharmaceuticals Latest Developments
11.2 Biogen
11.2.1 Biogen Company Information
11.2.2 Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.2.3 Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Biogen Main Business Overview
11.2.5 Biogen Latest Developments
11.3 Sobi
11.3.1 Sobi Company Information
11.3.2 Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.3.3 Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Sobi Main Business Overview
11.3.5 Sobi Latest Developments
11.4 Nippon Shinyaku
11.4.1 Nippon Shinyaku Company Information
11.4.2 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.4.3 Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Nippon Shinyaku Main Business Overview
11.4.5 Nippon Shinyaku Latest Developments
11.5 Jazz Pharmaceuticals
11.5.1 Jazz Pharmaceuticals Company Information
11.5.2 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
11.5.3 Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Jazz Pharmaceuticals Main Business Overview
11.5.5 Jazz Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Antisense Oligonucleotide Therapy for the Nervous System Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Intrathecal Injection
Table 4. Major Players of Intravenous Injections
Table 5. Major Players of Other
Table 6. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Table 9. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Table 12. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2019-2024)
Table 14. Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered
Table 15. Antisense Oligonucleotide Therapy for the Nervous System Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Table 20. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2019-2024)
Table 24. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Table 26. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Table 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Table 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2019-2024)
Table 34. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Antisense Oligonucleotide Therapy for the Nervous System
Table 40. Key Market Challenges & Risks of Antisense Oligonucleotide Therapy for the Nervous System
Table 41. Key Industry Trends of Antisense Oligonucleotide Therapy for the Nervous System
Table 42. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Ionis Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 47. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 48. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Ionis Pharmaceuticals Main Business
Table 50. Ionis Pharmaceuticals Latest Developments
Table 51. Biogen Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 52. Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 53. Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Biogen Main Business
Table 55. Biogen Latest Developments
Table 56. Sobi Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 57. Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 58. Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Sobi Main Business
Table 60. Sobi Latest Developments
Table 61. Nippon Shinyaku Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 62. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 63. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Nippon Shinyaku Main Business
Table 65. Nippon Shinyaku Latest Developments
Table 66. Jazz Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 67. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 68. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Jazz Pharmaceuticals Main Business
Table 70. Jazz Pharmaceuticals Latest Developments
Table 1. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Antisense Oligonucleotide Therapy for the Nervous System Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Intrathecal Injection
Table 4. Major Players of Intravenous Injections
Table 5. Major Players of Other
Table 6. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 7. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 8. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Table 9. Antisense Oligonucleotide Therapy for the Nervous System Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 10. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Table 12. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Player (2019-2024) & ($ millions)
Table 13. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player (2019-2024)
Table 14. Antisense Oligonucleotide Therapy for the Nervous System Key Players Head office and Products Offered
Table 15. Antisense Oligonucleotide Therapy for the Nervous System Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 19. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Table 20. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & ($ millions)
Table 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2019-2024)
Table 24. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 25. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Table 26. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 27. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Table 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Table 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 31. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 32. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Country (2019-2024) & ($ millions)
Table 33. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country (2019-2024)
Table 34. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 35. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 36. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Region (2019-2024) & ($ millions)
Table 37. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Type (2019-2024) & ($ millions)
Table 38. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size by Application (2019-2024) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Antisense Oligonucleotide Therapy for the Nervous System
Table 40. Key Market Challenges & Risks of Antisense Oligonucleotide Therapy for the Nervous System
Table 41. Key Industry Trends of Antisense Oligonucleotide Therapy for the Nervous System
Table 42. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Region (2025-2030) & ($ millions)
Table 43. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Region (2025-2030)
Table 44. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Type (2025-2030) & ($ millions)
Table 45. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Forecast by Application (2025-2030) & ($ millions)
Table 46. Ionis Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 47. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 48. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 49. Ionis Pharmaceuticals Main Business
Table 50. Ionis Pharmaceuticals Latest Developments
Table 51. Biogen Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 52. Biogen Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 53. Biogen Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 54. Biogen Main Business
Table 55. Biogen Latest Developments
Table 56. Sobi Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 57. Sobi Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 58. Sobi Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 59. Sobi Main Business
Table 60. Sobi Latest Developments
Table 61. Nippon Shinyaku Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 62. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 63. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 64. Nippon Shinyaku Main Business
Table 65. Nippon Shinyaku Latest Developments
Table 66. Jazz Pharmaceuticals Details, Company Type, Antisense Oligonucleotide Therapy for the Nervous System Area Served and Its Competitors
Table 67. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Product Offered
Table 68. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 69. Jazz Pharmaceuticals Main Business
Table 70. Jazz Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Antisense Oligonucleotide Therapy for the Nervous System Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Antisense Oligonucleotide Therapy for the Nervous System Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2023)
Figure 8. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type in 2023
Figure 10. Antisense Oligonucleotide Therapy for the Nervous System in Neuromuscular Diseases
Figure 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Antisense Oligonucleotide Therapy for the Nervous System in hATTR
Figure 13. Global Antisense Oligonucleotide Therapy for the Nervous System Market: hATTR (2019-2024) & ($ millions)
Figure 14. Antisense Oligonucleotide Therapy for the Nervous System in Other
Figure 15. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Other (2019-2024) & ($ millions)
Figure 16. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application in 2023
Figure 17. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player in 2023
Figure 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Figure 19. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 20. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 21. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 22. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Value Market Share by Country in 2023
Figure 24. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 25. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 26. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 27. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region in 2023
Figure 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 31. China Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 32. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 33. South Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 34. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 35. India Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 36. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 37. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country in 2023
Figure 38. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 39. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 40. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 41. France Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 42. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 43. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 44. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 45. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 49. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 50. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 51. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 52. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 53. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 54. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 55. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 56. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 57. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 58. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 59. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 60. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 61. China Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 62. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 63. Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 64. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 65. India Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 66. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 67. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 68. France Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 69. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 70. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 71. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 72. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 73. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 74. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 75. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 76. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 77. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Type (2025-2030)
Figure 78. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Antisense Oligonucleotide Therapy for the Nervous System Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Antisense Oligonucleotide Therapy for the Nervous System Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2023)
Figure 8. Antisense Oligonucleotide Therapy for the Nervous System Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type in 2023
Figure 10. Antisense Oligonucleotide Therapy for the Nervous System in Neuromuscular Diseases
Figure 11. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Neuromuscular Diseases (2019-2024) & ($ millions)
Figure 12. Antisense Oligonucleotide Therapy for the Nervous System in hATTR
Figure 13. Global Antisense Oligonucleotide Therapy for the Nervous System Market: hATTR (2019-2024) & ($ millions)
Figure 14. Antisense Oligonucleotide Therapy for the Nervous System in Other
Figure 15. Global Antisense Oligonucleotide Therapy for the Nervous System Market: Other (2019-2024) & ($ millions)
Figure 16. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application in 2023
Figure 17. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Player in 2023
Figure 18. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Figure 19. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 20. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 21. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 22. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2019-2024 ($ millions)
Figure 23. Americas Antisense Oligonucleotide Therapy for the Nervous System Value Market Share by Country in 2023
Figure 24. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 25. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 26. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 27. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 28. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region in 2023
Figure 29. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 30. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 31. China Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 32. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 33. South Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 34. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 35. India Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 36. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 37. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Country in 2023
Figure 38. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 39. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 40. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 41. France Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 42. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 43. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 44. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 45. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 49. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 50. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 51. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 52. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth 2019-2024 ($ millions)
Figure 53. Americas Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 54. APAC Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 55. Europe Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 56. Middle East & Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 57. United States Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 58. Canada Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 59. Mexico Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 60. Brazil Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 61. China Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 62. Japan Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 63. Korea Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 64. Southeast Asia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 65. India Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 66. Australia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 67. Germany Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 68. France Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 69. UK Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 70. Italy Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 71. Russia Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 72. Egypt Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 73. South Africa Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 74. Israel Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 75. Turkey Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 76. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Market Size 2025-2030 ($ millions)
Figure 77. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Type (2025-2030)
Figure 78. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Market Share Forecast by Application (2025-2030)
